TNGX Quote, Financials, Valuation and Earnings

EyePoint Plc has a net margin of 29.52% compared to Tango Therapeutics, Inc.'s net margin of -6183.44%. Tango Therapeutics, Inc.'s return on equity of -56.44% beat EyePoint Plc's return on equity of -79.15%.

Tango Therapeutics, Inc. has a consensus price target of $15.25, signalling upside risk potential of 25%. On the other hand EyePoint Plc has an analysts' consensus of $36.08 which suggests that it could grow by 135.38%. Given that EyePoint Plc has higher upside potential than Tango Therapeutics, Inc., analysts believe EyePoint Plc is more attractive than Tango Therapeutics, Inc..

Tango Therapeutics, Inc. has a beta of 1.750, which suggesting that the stock is 75.038% more volatile than S&P 500. In comparison EyePoint Plc has a beta of 1.758, suggesting its more volatile than the S&P 500 by 75.759%.

Tango Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tango Therapeutics, Inc. pays -- of its earnings as a dividend. EyePoint Plc pays out -- of its earnings as a dividend.

Tango Therapeutics, Inc. quarterly revenues are $53.8M, which are larger than EyePoint Plc quarterly revenues of $966K. Tango Therapeutics, Inc.'s net income of $15.9M is higher than EyePoint Plc's net income of -$59.7M. Notably, Tango Therapeutics, Inc.'s price-to-earnings ratio is -- while EyePoint Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tango Therapeutics, Inc. is 20.20x versus 24.84x for EyePoint Plc. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of 29.52% compared to Tango Therapeutics, Inc.'s net margin of 10.24%. Tango Therapeutics, Inc.'s return on equity of -56.44% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Tango Therapeutics, Inc. has a consensus price target of $15.25, signalling upside risk potential of 25%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.12%. Given that Tango Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Tango Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..

Tango Therapeutics, Inc. has a beta of 1.750, which suggesting that the stock is 75.038% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.

Tango Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tango Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Tango Therapeutics, Inc. quarterly revenues are $53.8M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Tango Therapeutics, Inc.'s net income of $15.9M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Tango Therapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tango Therapeutics, Inc. is 20.20x versus 7.34x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of 29.52% compared to Tango Therapeutics, Inc.'s net margin of -3135.32%. Tango Therapeutics, Inc.'s return on equity of -56.44% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Tango Therapeutics, Inc. has a consensus price target of $15.25, signalling upside risk potential of 25%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 104.68%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Tango Therapeutics, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Tango Therapeutics, Inc..

Tango Therapeutics, Inc. has a beta of 1.750, which suggesting that the stock is 75.038% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Tango Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tango Therapeutics, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Tango Therapeutics, Inc. quarterly revenues are $53.8M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Tango Therapeutics, Inc.'s net income of $15.9M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Tango Therapeutics, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tango Therapeutics, Inc. is 20.20x versus 31.37x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex, Inc. has a net margin of 29.52% compared to Tango Therapeutics, Inc.'s net margin of -44.78%. Tango Therapeutics, Inc.'s return on equity of -56.44% beat Teleflex, Inc.'s return on equity of -7.84%.

Tango Therapeutics, Inc. has a consensus price target of $15.25, signalling upside risk potential of 25%. On the other hand Teleflex, Inc. has an analysts' consensus of $129.25 which suggests that it could grow by 11.95%. Given that Tango Therapeutics, Inc. has higher upside potential than Teleflex, Inc., analysts believe Tango Therapeutics, Inc. is more attractive than Teleflex, Inc..

Tango Therapeutics, Inc. has a beta of 1.750, which suggesting that the stock is 75.038% more volatile than S&P 500. In comparison Teleflex, Inc. has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.269%.

Tango Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex, Inc. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.34 per share. Tango Therapeutics, Inc. pays -- of its earnings as a dividend. Teleflex, Inc. pays out 91.92% of its earnings as a dividend. Teleflex, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Tango Therapeutics, Inc. quarterly revenues are $53.8M, which are smaller than Teleflex, Inc. quarterly revenues of $913M. Tango Therapeutics, Inc.'s net income of $15.9M is higher than Teleflex, Inc.'s net income of -$408.9M. Notably, Tango Therapeutics, Inc.'s price-to-earnings ratio is -- while Teleflex, Inc.'s PE ratio is 25.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tango Therapeutics, Inc. is 20.20x versus 1.64x for Teleflex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.